{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"11"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"8"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}],"title":"Progressive Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}],"title":"Not Assessable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"21"}],"units":"Participants"}],"description":"Objective tumor response was measured using modified Response Evaluation Criteria in Solid Tumors (mRECIST) for assessment of response in malignant pleural mesothelioma (MPM). Per mRECIST for target lesions and assessed by CT: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease, those who fulfilled the criteria for neither PR nor PD; Progressive Disease (PD), \\>=20% increase in the sum of the longest diameter of target lesions.","groups":[{"description":"Weeks 1 and 3: CRS-207 (1 × 10\\^9 CFU)\n\nWeeks 5, 8, 11, 14, 17 and 20 (up to 6 cycles every 21 days): pemetrexed (500 mg/m\\^2) and cisplatin (75 mg/m\\^2)\n\nWeeks 23 and 26: CRS-207\n\nMaintenance Vaccinations: CRS-207 every 8 weeks (starting at Week 34) until disease progression\n\nImmunotherapy plus chemotherapy: live attenuated double deleted Lm","id":"OG000","title":"Immunotherapy Plus Chemotherapy"},{"description":"Weeks 1 and 3: cyclophosphamide (200 mg/m\\^2), CRS-207 (1 × 10\\^9 CFU)\n\nWeeks 5, 8, 11, 14, 17 and 20 (up to 6 cycles every 21 days): pemetrexed (500 mg/m\\^2) and cisplatin (75 mg/m\\^2)\n\nWeeks 23 and 26: cyclophosphamide one day before CRS-207\n\nMaintenance Vaccinations: cyclophosphamide one day before CRS-207 every 8 weeks (starting at Week 34) until disease progression\n\nImmunotherapy with cyclophosphamide plus chemotherapy: live attenuated double deleted Lm","id":"OG001","title":"Immunotherapy With Cyclophosphamide Plus Chemotherapy"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety analysis set: all enrolled subjects who received at least one dose of study treatment and had measurable disease.","reportingStatus":"POSTED","timeFrame":"Baseline to measured disease progression or death (up to 12 months or longer)","title":"Objective Tumor Response","type":"SECONDARY","unitOfMeasure":"Participants"}